Management's Plans for Continuing Operations (Details Textuals) (USD $)	6 Months Ended
Jun. 29, 2013
Management's Plans for Continuing Operations
Net profit	$ 478,803
Gain on sale of BluScience	2,891,917
Operating loss excluding gain of sale of BluScience assets	2,429,586
Share based compensation expense	728,349
Operating loss from BluScience excluding gain of sale of BluScience assets	192,399
Second payment toward additional payment amount	200,000
Additional amount expected to receive 2013 from sale of BluScience	$ 883,334

Amount of total revenue for the reportable segments, including revenue from external customers, transactions with other operating segments of the same entity, and (gross) interest revenue. All considered to be "operating revenue" for purposes of the taxonomy.

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 280

-SubTopic 10

-Section 50

-Paragraph 22

-Subparagraph (a),(b),(c)

-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Statement of Financial Accounting Standard (FAS)

-Number 131

-Paragraph 27

-Subparagraph a, b, c

-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Name:	us-gaap_SegmentReportingInformationRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration